Loading stock data…
ABOS
$2.19+0.02 (+0.92%)
After Hours$2.19+0.00 (+0.00%)· Last close Jun 9
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Acumen Pharmaceuticals, Inc. in the Healthcare sector is trading at $2.19. Wall Street consensus targets $7.40 (5 analysts), implying a +237.9% move over the next 12 months. The stock is currently 39% below its 52-week high of $3.60, remaining 0.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +237.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.19
Potential Downside
0%
Whystock Fair Value$2.19
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phas...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-129.49%
Volume
Today's trading volume
316,122
Recent News
Acumen Pharmaceuticals Inc (ABOS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
Acumen Pharmaceuticals Inc (ABOS) showcases promising developments in Alzheimer's treatment and cost management, despite reporting a net loss for the quarter.
Acumen Pharmaceuticals Q1 Earnings Call Highlights
Acumen Pharmaceuticals (NASDAQ:ABOS) said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results expected late in 2026, as the company continues to advance its broader Alzheimer’s disease pipeline. On the company’s first-quarter 2026 earnings call, Chief Executive Offic
Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.
Acumen Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
Moby summary of Acumen Pharmaceuticals, Inc.'s Q4 2025 earnings call